GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease

BACKGROUND: Agonism at the receptor for the glucose-dependent insulinotropic polypeptide (GIPR) is a key component of the novel unimolecular GIPR:GLP-1R co-agonists, which are among the most promising drugs in clinical development for the treatment of obesity and type 2 diabetes. The therapeutic eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Sachs, Stephan, Götz, Anna, Finan, Brian, Feuchtinger, Annette, DiMarchi, Richard D., Döring, Yvonne, Weber, Christian, Tschöp, Matthias H., Müller, Timo D., Hofmann, Susanna M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436634/
https://www.ncbi.nlm.nih.gov/pubmed/37592302
http://dx.doi.org/10.1186/s12933-023-01940-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436634/
https://www.ncbi.nlm.nih.gov/pubmed/37592302
http://dx.doi.org/10.1186/s12933-023-01940-2

Ejemplares similares